Kimberly E. Vanover is VP at Intra-Cellular Therapies, Inc. (ITCI). They have made 1 open-market trade across 1 company since 2016, most recently 2019-01-07.
CIK 0001585669
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ITCI | 37,224 | $4.9M |
Shares reported on the most recent Form 4, priced at the 2019-01-08 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ITCI | SELL | 2019-01-04 | 2019-01-08 | $11.52 | $117K | -1.3% | +3.2% | +4.2% |
| ITCI | SELL · 10b5-1 | 2019-01-02 | 2019-01-03 | $11.10 | $54K | +13.7% | +8.2% | +7.0% |
| ITCI | SELL · 10b5-1 | 2018-01-08 | 2018-01-10 | $17.46 | $13K | -0.5% | -12.0% | +16.4% |
| ITCI | SELL · 10b5-1 | 2018-01-05 | 2018-01-05 | $17.37 | $21K | +3.1% | -10.2% | +12.6% |
| ITCI | SELL · 10b5-1 | 2017-01-05 | 2017-01-09 | $16.59 | $13K | -19.4% | -18.5% | -14.6% |
| ITCI | SELL · 10b5-1 | 2016-12-15 | 2016-12-19 | $15.23 | $143K | -3.5% | -9.5% | -5.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.